Investment Objective. The Corgi Genomics & Precision Medicine ETF seeks capital appreciation.

Investors should consider the investment objectives, risks, charges, and expenses of each Fund carefully before investing. This and other important information is contained in the prospectus for each Fund, which can be obtained without charge from corgifunds.com or from the SEC at www.sec.gov. Read the applicable prospectus carefully before investing.

The Fund is newly organized and has limited operating history. There can be no assurance that the Fund will grow to or maintain an economically viable size. It may take time for the Fund to attract sufficient assets and for an active secondary market for its shares to develop or be sustained, which could result in wider bid-ask spreads, increased trading costs, or trading at a premium or discount to net asset value.

The information on this site is for informational purposes only and does not constitute investment, tax, or legal advice. Please consult your own investment, tax, and legal professionals regarding your specific situation.

The Funds’ shares are listed for trading on Cboe BZX Exchange, Inc. (the “Exchange”). The Funds are not sponsored, endorsed, sold, or promoted by the Exchange. The Exchange makes no representation regarding the advisability of investing in any Fund and is not responsible for, nor has it participated in, the determination of the timing of, prices of, or quantities of Fund shares to be issued or in the determination or calculation of the equation by which shares of any Fund are redeemable. The Exchange has no obligation or liability in connection with the administration, marketing, or trading of Fund shares.

Corgi Genomics & Precision Medicine ETF Risk. The Corgi Genomics & Precision Medicine ETF is subject to the investment risks associated with companies materially involved in the research, development, and commercialization of genomics and precision medicine technologies, including gene sequencing and analysis, bioinformatics and computational biology, molecular diagnostics and companion tests, gene editing and gene therapy platforms, targeted biologics and small molecule therapeutics, laboratory tools and reagents, clinical data platforms, and enabling services supporting personalized medicine. Because the Fund focuses on genomics and precision medicine companies, its performance will depend to a greater extent on clinical trial outcomes, FDA and international regulatory decisions, healthcare reimbursement policies, the pace of scientific advancement, patent protection and intellectual property disputes, and the commercial viability of novel therapeutic modalities. Many portfolio companies are pre-revenue or early-stage with significant cash burn and execution risk. Gene editing technologies face additional ethical scrutiny and regulatory uncertainty. Gene therapy pricing, which can exceed $2 million per treatment, creates reimbursement and market access challenges. As a concentrated and non-diversified fund, the Fund may be more volatile and more adversely affected by a single economic, regulatory, or technological development than a broadly diversified U.S. equity fund. The Fund is non-diversified and may invest a greater percentage of its assets in a limited number of issuers, increasing issuer-specific risk. Please see the Fund’s prospectus for a more complete discussion of these and other risks.

In addition, the fund is subject to general equity market volatility and may experience amplified fluctuation due to its industry concentration.

Investing involves risk, including possible loss of principal. There is no guarantee that any investment strategy or any Fund will achieve its objectives. Shares of the Funds are bought and sold on an exchange at market price and are not individually redeemable from the Funds. Market price will fluctuate, sometimes materially, and may be higher or lower than net asset value (“NAV”). Brokerage commissions, bid-ask spreads and other trading costs will reduce returns. Performance data represents past performance and does not guarantee future results. Investment return and principal value will fluctuate so that shares, when sold, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.

Premium/discount data shows the relationship between the market price of a Fund’s shares and that Fund’s NAV. Historical premium/discount data may not be indicative of future premium/discount levels.

The Fund issues and redeems shares only in large blocks called “Creation Units” at NAV next determined after an order is accepted. Only authorized participants (“APs”) may transact in Creation Units directly with the Fund. Investors should contact their broker or financial intermediary to place trades.

This site is intended only for investors resident in the United States. Nothing on this website is an offer to sell, or a solicitation of an offer to buy, any security in any jurisdiction where such offer or solicitation would be unlawful.

Corgi ETF Trust I. Investment adviser: Corgi Strategies, LLC. Distributor: Paralel Distributors LLC. Member Firm. Paralel is unaffiliated with Corgi Strategies, LLC, The Corgi Company. © 2026 Corgi Strategies, LLC. All rights reserved.